Back to Search Start Over

Oxygen-Deficient Molybdenum Oxide Nanosensitizers for Ultrasound-Enhanced Cancer Metalloimmunotherapy.

Authors :
Wang Y
Gong F
Han Z
Lei H
Zhou Y
Cheng S
Yang X
Wang T
Wang L
Yang N
Liu Z
Cheng L
Source :
Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2023 Feb 20; Vol. 62 (9), pp. e202215467. Date of Electronic Publication: 2023 Jan 24.
Publication Year :
2023

Abstract

Oxygen-deficient molybdenum oxide (MoO <subscript>X</subscript> ) nanomaterials are prepared as novel nanosensitizers and TME-stimulants for ultrasound (US)-enhanced cancer metalloimmunotherapy. After PEGylation, MoO <subscript>X</subscript> -PEG exhibits efficient capability for US-triggered reactive oxygen species (ROS) generation and glutathione (GSH) depletion. Under US irradiation, MoO <subscript>X</subscript> -PEG generates a massive amount of ROS to induce cancer cell damage and immunogenic cell death (ICD), which can effectively suppress tumor growth. More importantly, MoO <subscript>X</subscript> -PEG itself further stimulates the maturation of dendritic cells (DCs) and triggeres the activation of the cGAS-STING pathway to enhance the immunological effect. Due to the robust ICD induced by SDT and efficient DC maturation stimulated by MoO <subscript>X</subscript> -PEG, the combination treatment of MoO <subscript>X</subscript> -triggered SDT and aCTLA-4 further amplifies antitumor therapy, inhibits cancer metastases, and elicits robust immune responses to effectively defeat abscopal tumors.<br /> (© 2023 Wiley-VCH GmbH.)

Details

Language :
English
ISSN :
1521-3773
Volume :
62
Issue :
9
Database :
MEDLINE
Journal :
Angewandte Chemie (International ed. in English)
Publication Type :
Academic Journal
Accession number :
36591974
Full Text :
https://doi.org/10.1002/anie.202215467